Abu Dhabi Health Data Services, Syndesis Health collaborate to advance AI-driven genomic analytics, drug discovery
ABU DHABI (WAM)Abu Dhabi Health Data Services (ADHDS), part of M42's Digital Health Solutions (DHS) platform, has announced a collaboration with Syndesis Health, one of the world's largest holders of phenotype data, encompassing over 70 million patient profiles.The term sheet was signed by Kareem Shahin, CEO of M42's Digital Health Solutions platform and Josh Sutton, CEO of Syndesis Health, reinforcing Abu Dhabi's position as a global hub for digital health innovation.This collaboration brings together Syndesis Health's extensive phenotype database and ADHDS's cutting-edge digital health infrastructure to drive advancements in AI-powered genomic analytics, precision medicine, and drug discovery.By combining real-world data with advanced artificial intelligence, the collaboration aims to accelerate innovation in clinical decision support and pharmaceutical research, ultimately improving treatment pathways for patients worldwide.The partnership will focus on three key areas:- Commercialising phenotype data to support global pharmaceutical, biotech, and academic research- Developing AI-driven predictive models that enable personalised and data-driven healthcare while maintaining strict compliance with international data governance standards-Enhancing genomic analytics to improve prescription safety and reduce adverse drug reactions through AI-powered pharmacogenomicsBy leveraging their complementary capabilities, the parties have signed a term sheet outlining their intent to establish a joint venture focused on generating valuable insights to accelerate drug development, enhance patient outcomes, and support the advancement of the healthcare infrastructure. This potential collaboration aligns with the Abu Dhabi's vision of positioning itself as global leader in digital health and biomedical research.Kareem Shahin, CEO of M42's Digital Health Solutions platform, emphasised the significance of the partnership, stating, "This collaboration represents a major step forward in harnessing real-world data and AI to transform healthcare. By integrating Syndesis Health's vast phenotype dataset with our digital health expertise, we are opening new frontiers in genomic analytics and drug discovery."Josh Sutton, CEO of Syndesis Health, added, "The collaboration between Syndesis Health and ADHDS will generate groundbreaking insights that accelerate pharmaceutical innovation and improve patient outcomes. Together, we are setting new benchmarks for AI-driven healthcare solutions."
With a shared commitment to advancing global healthcare through data-driven innovation, this partnership marks a significant milestone in the evolution of precision medicine and AI-powered drug discovery.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
3 days ago
- Zawya
UAE: 'Malaffi' reaches 3.5bln clinical records
Malaffi, the region's first Health Information Exchange (HIE) platform and a strategic initiative of the Department of Health – Abu Dhabi (DoH), operated by M42's Abu Dhabi Health Data Services (ADHDS), has reached 3.5 billion clinical records, representing 12.7 million patient profiles across Abu Dhabi to help progress the UAE's advance in precision and preventive care. The milestone highlights Malaffi's ongoing evolution as a cutting-edge Health Information Exchange platform that supports innovation and excellence in the delivery of healthcare services. With connections to nearly all healthcare facilities – including hospitals, clinics and pharmacies - in the Emirate, Malaffi now supports 53,476 authorised users, from doctors and nurses to allied health professionals across 3,072 healthcare facilities in Abu Dhabi. The platform's latest enhancements expand its capabilities with the addition of over 160,000 M42 Pharmacogenomics Reports, offering personalised insights into patients' genetic responses to medications to optimise treatment plans. Furthermore, new diagnostic test results across key specialities, such as Mental Health, Ophthalmology, Otolaryngology, and Respiratory Diagnostics, provide clinicians with deeper insights to elevate patient care. These advancements are complemented by features like the Radiology Image Exchange, allowing access to radiology images from over 60 facilities to all authorised clinical users, and the AI-powered Patient Risk Profile, which predicts risks for chronic conditions and acute events. Together, these innovations streamline workflows, enhance decision-making and support better healthcare outcomes. Dr. Noura Khamis Al Ghaithi, Undersecretary of the DoH, said, 'Malaffi's access to 3.5 billion medical records marks a pivotal milestone, reflecting the DoH's steadfast commitment to creating the world's most intelligent, patient-centric healthcare system. By harnessing innovative healthcare solutions powered by artificial intelligence, such as pharmacogenomics and predictive analytics, Malaffi continues to advance, enabling healthcare providers to deliver services that meet the highest standards of care and empower community members to lead healthier lives.' Kareem Shaheen, CEO of M42's Digital Health Solutions platform, stated, 'This milestone is a testament to the collaborative efforts of Abu Dhabi's healthcare ecosystem and the visionary leadership of the DoH. Aligned with M42's mission to advance innovation in health for people, Malaffi is securely connecting critical patient information with clinicians to enable informed decision-making, elevate healthcare standards and deliver quality patient outcomes.' With 3.5 billion clinical records now connected, Malaffi plays a key role in enhancing Abu Dhabi's healthcare ecosystem and providing a strong foundation for research, from AI-driven analytics to advanced treatments.
Al Etihad
4 days ago
- Al Etihad
Abu Dhabi: Malaffi reaches 3.5 billion clinical records
14 Aug 2025 11:36 ABU DHABI (ALETIHAD) Malaffi, the region's first Health Information Exchange (HIE) platform and a strategic initiative of the Department of Health – Abu Dhabi (DoH), operated by M42's Abu Dhabi Health Data Services (ADHDS), has achieved a significant milestone by reaching 3.5 billion clinical records, representing 12.7 million unique patient profiles across Abu Dhabi to help progress the UAE's advance in precision and preventive care. The milestone highlights Malaffi's ongoing evolution as a cutting-edge Health Information Exchange platform that supports innovation and excellence in the delivery of healthcare services. Malaffi continues to improve healthcare professionals' access to and utilisation of critical patient information. With connections to nearly all healthcare facilities – including hospitals, clinics and pharmacies - in the Emirate, Malaffi now supports 53,476 authorised users, from doctors and nurses to allied health professionals across 3,072 healthcare facilities in Abu platform's latest enhancements expand its capabilities with the addition of over 160,000 M42 Pharmacogenomics Reports, offering personalised insights into patients' genetic responses to medications to optimise treatment plans. Furthermore, new diagnostic test results across key specialities—such as Mental Health, Ophthalmology, Otolaryngology, and Respiratory Diagnostics—provide clinicians with deeper insights to elevate patient advancements are complemented by features like the Radiology Image Exchange, allowing access to radiology images from over 60 facilities to all authorised clinical users, and the AI-powered Patient Risk Profile, which predicts risks for chronic conditions and acute events. Together, these innovations streamline workflows, enhance decision-making and support better healthcare Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: 'Malaffi's access to 3.5 billion medical records marks a pivotal milestone, reflecting the Department of Health – Abu Dhabi's steadfast commitment to creating the world's most intelligent, patient-centric healthcare system." She added: "By harnessing innovative healthcare solutions powered by artificial intelligence, such as pharmacogenomics and predictive analytics, Malaffi continues to advance, enabling healthcare providers to deliver services that meet the highest standards of care and empower community members to lead healthier lives. This achievement further strengthens Abu Dhabi's position as a globally leading digital healthcare ecosystem.'Kareem Shaheen, CEO of M42's Digital Health Solutions platform, added: "This milestone is a testament to the collaborative efforts of Abu Dhabi's healthcare ecosystem and the visionary leadership of the Department of Health." He added: "Aligned with M42's mission to advance innovation in health for people, Malaffi is securely connecting critical patient information with clinicians to enable informed decision-making, elevate healthcare standards and deliver quality patient outcomes. With every new feature and service we introduce, we are revolutionising the way care is delivered, ensuring better outcomes for patients and providers alike." With 3.5 billion clinical records now connected, Malaffi plays a key role in enhancing Abu Dhabi's healthcare ecosystem and providing a strong foundation for research, from AI-driven analytics to advanced treatments. As Abu Dhabi progresses in its digital transformation, Malaffi supports the Emirate's growth by offering innovative solutions that benefit patients and providers, reinforcing its position as a global hub for healthcare innovation. Source: Aletihad - Abu Dhabi
Khaleej Times
06-08-2025
- Khaleej Times
UAE: AI outperforms human radiologists, records zero false negatives
A comprehensive study on an AI model developed by Abu Dhabi-based healthcare group M42 has found that it can safely and accurately detect tuberculosis from chest X-rays — outperforming human radiologists. Published in the prestigious scientific journal npj Digital Medicine – Nature, the study conducted in collaboration with Abu Dhabi's Capital Health Screening Centre (CHSC) is among the largest real-world clinical validations of an AI-driven healthcare solution to date, analyzing over one million chest X-rays to evaluate the efficacy and scalability of AI in TB screening. The study assessed AI Radiology in Screening TB (AIRIS-TB), M42's cutting-edge AI model engineered to streamline routine tuberculosis screenings, allowing radiologists to focus on more complex or urgent cases. The model demonstrated exceptional performance, indicating high diagnostic accuracy and an unprecedented 0 percent of false negatives. This means that the model has the potential to safely automate up to 80 percent of routine chest X-ray assessments, directly reducing the workload of radiologists, minimising the risk of human error, and delivering significant cost efficiencies in high-throughput low-prevalence settings. Labour-intensive Currently, reviews of chest X-rays remains labor-intensive and prone to oversight and error, potentially leading to missed or delayed diagnoses. A prior study has indicated a 26.6 percent increase in missed findings when radiologists double their annotation speed, and a rise in errors after 9 hours into their shift. AIRIS-TB delivered consistently strong performance across a wide range of demographic groups, including variations in gender, age, HIV status, income levels, and a diverse population covering six World Health Organization (WHO) regions, highlighting the model's robustness, fairness and generalizability across diverse global populations. These results indicate the model's potential to significantly improve clinical workflows and drive earlier, more equitable screening of TB in high-volume programs worldwide. "This landmark study marks a pivotal moment in the potential power of AI in the global fight against tuberculosis,' said Dimitris Moulavasilis, Group CEO of M42. 'Our AIRIS-TB model stands as a compelling testament to the unmatched accuracy, safety and scalability that AI can deliver, particularly in resource-limited settings where there is a shortage of radiologists and the need to tackle TB is greatest.' He added that in regions with a high prevalence of TB, the model offers a 'scalable technological solution' that can help save lives. 'These results signal the transformative role AI can play in reshaping global public health and redefining how healthcare is diagnosed, delivered and experienced worldwide,' he said. The study underwent rigorous peer review and ethical oversight by the Department of Health – Abu Dhabi, ensuring transparency, accountability, and the highest standards of clinical integrity. Its publication in a leading scientific journal reinforces M42's position as a global pioneer in AI-led health solutions and solidifies the UAE's growing prominence as a global, data-driven hub for cutting-edge medical innovation and technology.
